AN. 5. 2004 2:59PM

UNITED STATES OF AMERICA

DECLARATION FOR PATENT APPLICATION

s a belov	w named inventor(s), I/We h		·
•	and for which a patent is	n/we are the original, first to a sought on the invention e	citizenship(s) are as stated below my name(s). and sole/joint inventor(s) of the subject matter which is claimed entitled:
1	Method for Determ	aining Specific Groups C	onstituting Heparins or Low Molecular Weight Heparins
:	and the specification of (check one)	was filed on and was amo	nereto (Aventis Docket No. FRAV2002/0026US NP) September 18, 2003 as U.S. Application Number 10/665,872 ended on (if applicable). ed and claimed in PCT Int'l Application Number filed on as amended under PCT Article 19 on (if any).
,	including the claims as I/We acknowledge the be material to patentab	amended by any amendment duty to disclose to the U.S ility as defined in 37 C.F.R	. Patent and Trademark Office all mormation known to moras to . 1.56.
	application(s) for patent least one other country	t or inventor's certificate, o other than the United States of priority is claimed. I We	Fitle 35, United States Code §119(a)-(d) or 365 (b) of any foreign r 365(a) of any PCT international application which designated at es of America, listed below and having a filing date before that of a have also identified below any foreign application for patent or at of the application on which priority is claimed:
Foreign Priority:		France Country	23 September 2002 Day/Month/Year Filed
Prior Foreign Appin(s		Country	Day/Month/Year Filed
\boxtimes			United States Code §119(e) of any United States Provisional
1	application(s) listed be	BIOM:	
,	60/422,482 Number	31 October 2002 Filing Date	· · ·
: 	Number I/We hereby claim the application(s) or intermediate of each of the control to the first provided by the first profession which is profession which it is profession w	31 October 2002 Filing Date se benefit under Title 35 sational application design laims of this application is paragraph of Title 35, United 15, United 1	i, United States Code §120 or 365(c) of any United States ating the United States listed below and, insofar as the subject not disclosed in the prior United States application in the manner ited States Code §112, I/We acknowledge the duty to disclose defined in Title 37, Code of Federal Regulations §1.56 which prior application and the national or PCT International filing date of
	Number I/We hereby claim the application(s) or intermediate of each of the control provided by the first information which is not became available between	31 October 2002 Filing Date the benefit under Title 35 testional application designations of this application is baragraph of Title 35, United and the patentability as ween the filing date of the patentability.	ating the United States listed below and, insorar as the subject not disclosed in the prior United States application in the manner ited States Code §112, I/We acknowledge the duty to disclose defined in Title 37. Code of Federal Regulations §1.56 which
and belie	60/422,482 Number I/We hereby claim the application(s) or intermetter of each of the control provided by the first provided by the samplication. Application Serial No. Reby declare that all statement are believed to be true; and the sampling specific provided by the sampling sp	31 October 2002 Filing Date the benefit under Title 35 stational application designations of this application is baragraph of Title 35, Uninaterial to patentability as ween the filing date of the prints made herein of my own of further that these staters by fine or imprisonment.	ating the United States listed below and, insorar as the subject not disclosed in the prior United States application in the manner ited States Code §112, I/We acknowledge the duty to disclose defined in Title 37, Code of Federal Regulations §1.56 which prior application and the national or PCT International filing date of
and belie and the l villful fal	Number I/We hereby claim the application(s) or intermediate of each of the conformation which is not became available between this application. Application Serial Note the conformation which is not became available between the application. Application Serial Note that all statements are believed to be true; allike so made are punishable se statements may jeopardiate.	31 October 2002 Filing Date the benefit under Title 35 stational application designations of this application is baragraph of Title 35, Uninaterial to patentability as ween the filing date of the prints made herein of my own of further that these staters by fine or imprisonment.	ating the United States listed below and, insorar as the subject not disclosed in the prior United States application in the manner ited States Code §112, I/We acknowledge the duty to disclose defined in Title 37, Code of Federal Regulations §1.56 which prior application and the national or PCT International filing date of Status (Patented, Pending) In knowledge are true and that all statements made on information ments were made with the knowledge that willful false statements or both, under Title 18, United States code §1001, and that such cation or any patent Issued thereon.
and belie and the l villful fal nventors	Number I/We hereby claim the application(s) or intermediate of each of the conformation which is not became available between this application. Application Serial Note the conformation which is not became available between the application. Application Serial Note that all statements are believed to be true; allike so made are punishable se statements may jeopardiate.	31 October 2002 Filing Date the benefit under Title 35 that an application designations of this application is baragraph of Title 35, Uninaterial to patentability as ween the filing date of the particular par	ating the United States listed below and, insorar as the subject not disclosed in the prior United States application in the manner ited States Code §112, I/We acknowledge the duty to disclose defined in Title 37, Code of Federal Regulations §1.56 which prior application and the national or PCT International filing date of Status (Patented, Pending) In knowledge are true and that all statements made on information ments were made with the knowledge that willful false statements or both, under Title 18, United States code §1001, and that such cation or any patent Issued thereon. 2. Full name: Christian VISKOV
and belie and the l villful fal nventors	Number I/We hereby claim the application(s) or intermediate of each of the convolved by the first provided by	31 October 2002 Filing Date the benefit under Title 35 that an application designations of this application is baragraph of Title 35, Uninaterial to patentability as ween the filing date of the particular par	ating the United States listed below and, insorar as the subject not disclosed in the prior United States application in the manner ited States Code §112, I/We acknowledge the duty to disclose defined in Title 37. Code of Federal Regulations §1.56 which prior application and the national or PCT International filing date of Status (Patented, Pending) In knowledge are true and that all statements made on information ments were made with the knowledge that willful false statements or both, under Title 18, United States code §1001, and that such eation or any patent Issued thereon. Ached. 2. Full name: Christian VISKOV
and belie and the l villful fal- nventors 1. Full nar Signature: Date:	Number I/We hereby claim the application(s) or intermediate of each of the convolved by the first provided by	31 October 2002 Filing Date the benefit under Title 35 that an application designations of this application is baragraph of Title 35, Uninaterial to patentability as ween the filing date of the particular par	ating the United States listed below and, insorar as the subject not disclosed in the prior United States application in the manner ited States Code §112, I/We acknowledge the duty to disclose defined in Title 37. Code of Federal Regulations §1.56 which prior application and the national or PCT International filing date of Status (Patented, Pending) In knowledge are true and that all statements made on information ments were made with the knowledge that willful false statements or both, under Title 18, United States code §1001, and that such exation or any patent Issued thereon. 2. Full name: Christian VISKOV Signature:
nd belie and the l villful fall nventors l. Full nar Signature: Date:	Number I/We hereby claim the application(s) or intermediate of each of the convolved by the first period of the convolved between the convolved by the first period of the convolved by the convolved	31 October 2002 Filing Date the benefit under Title 35 stational application designations of this application is paragraph of Title 35. Unimaterial to patentability as ween the filing date of the paragraph of	ating the United States listed below and, insorar as the subject not disclosed in the prior United States application in the manner ited States Code §112, I/We acknowledge the duty to disclose defined in Title 37. Code of Federal Regulations §1.56 which prior application and the national or PCT International filing date of Status (Patented, Pending) In knowledge are true and that all statements made on information ments were made with the knowledge that willful false statements or both, under Title 18, United States code §1001, and that such exation or any patent Issued thereon. 2. Full name: Christian VISKOV Signature:
and belie and the l villful fal nventors l. Full nar Signature: Date: ————————————————————————————————————	Number I/We hereby claim the application(s) or intermediate of each of the convolved by the first provided by	31 October 2002 Filing Date the benefit under Title 35 stational application designations of this application is paragraph of Title 35. Uninaterial to patentability as ween the filing date of the paragraph of Title 35. Uninaterial to patentability as ween the filing date of the paragraph of the application of the paragraph of	ating the United States listed below and, insorar as the subject not disclosed in the prior United States application in the manner ted States Code §112, I/We acknowledge the duty to disclose defined in Title 37, Code of Federal Regulations §1.56 which or application and the national or PCT International filing date of Status (Patented, Pending) In knowledge are true and that all statements made on information ments were made with the knowledge that willful false statements or both, under Title 18, United States code \$1001, and that such cation or any patent Issued thereon. 2. Full name: Christian VISKOV Signature:

3. Full name:	4. Full name:
Signature:	Signature:
Date:	Date:
Country of Citizenship:	Country of Citizenship:
Residence: (City and State/City and Country only)	
(City and State/City and Country only)	(City and State/City and Country only)
P. O. Address:	P. O. Address:
	,
	,
5. Full name:	6. Full name:
5. Full name:	6. Full name:
Signature:	Signature:
Signature;	Signature:
Signature;	Signature: Date: Country of Citizenship:
5. Full name: Signature: Date: Country of Citizenship: Residence: (City and State/City and Country only)	Signature:

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206
P.O. Box 6800
Mail Code D-303A
Bridgewater, NJ 08807-0800
Telephone (908) 231-2387
Telefax (908) 231-2626

Aventis Docket No. FRAV2002/0026 US NP

Aventis Docket No. FRAV2002/0026 US NP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

pplicants: Pierre Mourier, tal

Examiner:

Not Yet Assigned

Serial No.: 10/665,872

Group Art Unit:

Not Yet Assigned

Filed:

September 18, 2003

Title: METHOD FOR DETERMINING SPECIFIC GROUPS CONSTITUTING HEPARINS OR LOW MOLECULAR WEIGHT HEPARINS

POWER OF ATTORNEY FOR PATENT APPLICATION

Mail Stop Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

, an Authorized Signatory of Aventis Pharma S.A., Assignee of the above-identified Application, hereby appoint the attorneys and/or agents associated with the Customer No.(s) provided below as attorneys and/or agents with full power to prosecute this application on behalf of Assignee and to transact all of Assignee's business in connection with the above-identified Application in the Patent and Trademark Office:

Customer No.: 005487

Effective Date:

September 18, 2003

By:

ROUSSEAU Pierrick

Title:

Executive

Date:

October 20, 2003

Address correspondence and telephone calls to: Joseph Strupczewski, Reg. No. 50,903 Aventis Pharmaceuticals Inc. Patent Department Route #202-206 / P.O. Box 6800 Bridgewater, New Jersey 08807-0800 Telephone (908) 231-2387 Telefax (908) 231-2626